Remeglurant (INN ; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]
Clinical data | |
---|---|
Other names | MRZ-8456 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H15BrN4O |
Molar mass | 371.238 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). World Health Organization.
- ^ US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
- ^ a b "Remeglurant". Adis Insight. Springer Nature Switzerland AG.